穿支动脉粥样硬化病患者早期神经功能恶化的研究进展

doi:10.3969/j.issn.1673-5765.2023.10.013

摘要/Abstract

摘要： 穿支动脉粥样硬化病患者发病后容易发生早期神经功能恶化，导致患者功能预后不佳，给临床医师带来极大挑战。目前穿支动脉粥样硬化病患者早期神经功能恶化的发病机制尚未阐明，且在治疗方面缺乏有力的循证医学证据，一些观察性研究显示强化抗栓的策略可能是合理的。本文对穿支动脉粥样硬化病患者早期神经功能恶化的发病机制、风险预测及干预策略等方面的研究进行综述，以期提高临床医师的认识。

文章导读： BAD易发生END，其机制可能与穿支动脉开口处的动脉硬化斑块及血栓形成和延伸有关。临床急需准确预测END发生风险的方法。进一步增强抗栓可能是应对BAD患者END的有效策略，期待临床提供更多的循证证据。

关键词: 穿支动脉粥样硬化病; 早期神经功能恶化; 风险预测; 强化抗栓

Abstract: Patients with branch atheromatous disease (BAD) are prone to arteriosclerosis early neurological deterioration (END), which leads to poor functional prognosis and poses a great challenge to clinicians. At present, the pathogenesis of END in patients with BAD has not been elucidated, and there is a lack of strong evidence-based medical evidence in terms of treatment, with some observational studies suggesting that strategies of enhanced antithrombotic therapy may be justified. This paper reviews the research on the mechanism, risk prediction and intervention strategy of END in BAD patients in order to improve the awareness and attention of clinicians.

Key words: Branch atheromatous disease; Early neurological deterioration; Risk prediction; Enhanced antithrombotic therapy

王璐, 王健. 穿支动脉粥样硬化病患者早期神经功能恶化的研究进展[J]. 中国卒中杂志, 2023, 18(10): 1191-1195.

WANG Lu, WANG Jian. Advances in the Study of Early Neurological Deterioration in Patients with Branch Atheromatous Disease[J]. Chinese Journal of Stroke, 2023, 18(10): 1191-1195.

参考文献

[1] CAPLAN L R. Intracranial branch atheromatous disease：a neglected，understudied，and underused concept[J]. Neurology，1989，39（9）：1246-1250.
[2] PETRONE L，NANNONI S，DEL BENE A，et al. Branch atheromatous disease：a clinically meaningful，yet unproven concept[J]. Cerebrovasc Dis，2016，41（1/2）：87-95.
[3] YAMAMOTO Y，OHARA T，HAMANAKA M，et al. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits[J]. J Neurol Sci，2011，304（1/2）：78-82.
[4] XU J H，XU X J，WANG H，et al. Dual antiplatelet therapy plus argatroban prevents early neurological deterioration in branch atherosclerosis disease[J/OL]. Stroke，2022，53（1）：e19-e20[2022-07-28]. https://doi.org/10.1161/STROKEAHA.121.036356.
[5] JIANG S，YAN Y Y，YANG T，et al. Plaque distribution correlates with morphology of lenticulostriate arteries in single subcortical infarctions[J]. Stroke，2020，51（9）：2801-2809.
[6] LIM S H，CHOI H，KIM H T，et al. Basilar plaque on high- resolution MRI predicts progressive motor deficits after pontine infarction[J]. Atherosclerosis，2015，240（1）：278-283.
[7] YAN Y Y，JIANG S，YANG T，et al. Lenticulostriate artery length and middle cerebral artery plaque as predictors of early neurological deterioration in single subcortical infarction[J]. Int J Stroke，2023，18（1）：95-101.
[8] JANG S H，PARK S W，KWON D H，et al. The length of an infarcted lesion along the perforating artery predicts neurological deterioration in single subcortical infarction without any relevant artery stenosis[J/OL]. Front Neurol，2020，11：553326[2022-07-28]. https://doi.org/10.3389/fneur.2020.553326.
[9] KALOWSKA E，ROSTRUP E，ROSENBAUM S，et al. Acute MRI changes in progressive ischemic stroke[J]. Eur Neurol，2008，59（5）：229-236.
[10] GÖKÇAL E，NIFTALIYEV E，BARAN G，et al. Progressive deficit in isolated pontine infarction：the association with etiological subtype，lesion topography and outcome[J]. Acta Neurol Belg，2017，117（3）：649-654.
[11] OHARA T，YAMAMOTO Y，TAMURA A，et al. The infarct location predicts progressive motor defificits in patients with acute lacunar infarction in the lenticulostriate artery territory[J]. J Neurol Sci，2010，293（1/2）：87-91.
[12] KONISHI J，YAMADA K，KIZU O，et al. MR tractography for the evaluation of functional recovery from lenticulostriate infarcts[J]. Neurology，2005，64（1）：108-113.
[13] YAMADA M，YOSHIMURA S，KAKU Y，et al. Prediction of neurologic deterioration in patients with lacunar infarction in the territory of the lenticulostriate artery using perfusion CT[J]. AJNR Am J Neuroradiol，2004，25（3）：402-408.
[14] HUANG Y C，TSAI Y H，LEE J D，et al. Hemodynamic factors may play a critical role in neurological deterioration occurring within 72 hrs after lacunar stroke[J/OL]. PLoS One，2014，9（10）：e108395[2022-07-28]. https://doi.org/10.1371/journal.pone.0108395.
[15] MEN X J，LI J J，ZHANG B J，et al. Homocysteine and C-reactive protein associated with progression and prognosis of intracranial branch atheromatous disease[J/OL]. PLoS One，2013，8（9）：e73030[2022-07-28]. https://doi.org/10.1371/journal.pone.0073030.
[16] BI X W，LIU X Q，CHENG J Q. Monocyte to high-density lipoprotein ratio is associated with early neurological deterioration in acute isolated pontine infarction[J/OL]. Front Neurol，2021，12：678884[2022-07-28]. https://doi.org/10.3389/fneur.2021.678884.
[17] MIYAMOTO N，TANAKA R，UENO Y，et al. Analysis of the usefulness of the WORSEN score for predicting the deterioration of acute ischemic stroke[J]. J Stroke Cerebrovasc Dis，2017，26（12）：2834-2839.
[18] GONG P，ZHANG X，GONG Y，et al. A novel nomogram to predict early neurological deterioration in patients with acute ischaemic stroke[J]. Eur J Neurol，2020，27（10）：1996-2005.
[19] 门雪娇，陈玮琪，许玉园，等. 穿支动脉粥样硬化病中国专家共识[J]. 中国卒中杂志，2021，16（5）：508-514.
MEN X J，CHEN W Q，XU Y Y，et al. Chinese experts consensus on branch atheromatous disease[J]. Chin J Stroke，2021，16（5）：508-514.
[20] 中国卒中学会，中国卒中学会神经介入分会，中华预防医学会卒中预防与控制专业委员会介入学组. 替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J]. 中国卒中杂志，2019，14（10）：1034-1044.
Chinese Stroke Association，Chinese Interventional Neuroradiology Society，Intervention Group of Committee of Stroke Prevention and Control of Chinese Preventive Medicine Association. Chinese experts consensus on clinical application of tirofiban in atherosclerotic cerebrovascular diseases[J]. Chin J Stroke，2019，14（10）：1034-1044.
[21] 北京神经科学学会血管神经病学专业委员会，阿加曲班治疗急性缺血性卒中中国专家共识组. 阿加曲班治疗急性缺血性卒中中国专家共识2021[J]. 中国卒中杂志，2021，16（9）：946-953.
Vascular Neurology Committee，Beijing Neuroscience Society，Experts Group of Chinese Consensus on Argatroban for Treatment of Acute Ischemic Stroke. Chinese consensus on argatroban for treatment of acute ischemic stroke 2021[J]. Chin J Stroke，2021，16（9）：946-953.
[22] WU C J，SUN C H，WANG L J，et al. Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis[J]. Stroke，2019，50（12）：3481-3487.
[23] HE L Y，XU R H，WANG J，et al. Capsular warning syndrome：clinical analysis and treatment[J/OL]. BMC Neurol，2019，19（1）：285[2022-07-28]. https://doi.org/10.1186/s12883-019-1522-0.
[24] PARK M G，OH E H，KIM B K，et al. Intravenous tissue plasminogen activator in acute branch atheromatous disease：does it prevent early neurological deterioration?[J/OL]. J Clin Neurosci，2016，33：194-197[2022-07-28]. https://doi.org/10.1016/j.jocn.2016.04.011.
[25] WU X B，LIU Y，NIE C，et al. Efficacy and safety of intravenous thrombolysis on acute branch atheromatous disease：a retrospective case-control study[J/OL]. Front Neurol，2020，11：581[2022-07-28]. https://doi.org/10.3389/fneur.2020.00581.
[26] LI W，WU Y，LI X S，et al. Intravenous tirofiban therapy for patients with capsular warning syndrome[J]. Stroke Vasc Neurol，2019，4（1）：22-27.
[27] LI W，LIN L，ZHANG M，et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke，2016，47（10）：2649-2651.
[28] NISHI R，MANO T，KOBAYASHI Y，et al. Argatroban，aspirin，and clopidogrel combination therapy for acute penetrating artery infarction：a pilot study[J]. Brain Nerve，2016，68（2）：181-189.
[29] KIMURA T，TUCKER A，SUGIMURA T，et al. Ultra-early combination antiplatelet therapy with cilostazol for the prevention of branch atheromatous disease：a multicenter prospective study[J]. Cerebrovasc Dis Extra，2016，6（3）：84-95.